ArticleESC heart failure2026
Contemporary real-world treatment of cardiac transthyretin amyloidosis with tafamidis: a long-term multicentre study.
Article in ESC heart failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
aimsTafamidis was the first drug approved for transthyretin amyloid cardiomyopathy (ATTR-CM), but contemporary real-world evidence is lacking. METHODS AND
resultsThis retrospective, multicentre study included ATTR-CM patients enrolled after commercial availability of tafamidis 61 mg in Germany (April 2020 to March 2021), with treatment initiation based on physician clinical judgement. Primary and secondary endpoints were all-cause mortality and the composite of all-cause mortality and/or heart failure (HF) hospitalization, respectively. The cohort comprised 329 patients (median age 80 [76-83] years, 85% male and 8% variant ATTR) and 80% received tafamidis. During a median follow-up of 39 [18-48] months, 21% of patients died and 42% reached the composite endpoint. Tafamidis-treated patients had a 3-year survival of 86% and an event-free survival of 63%. After propensity-score matching for age, New York Heart Association (NYHA) class, National Amyloidosis Centre (NAC) stage, and serum albumin, tafamidis was significantly associated with lower all-cause mortality (hazard ratio [HR] 0.28; 95%-confidence interval [CI] 0.13-0.61; P = .001) and fewer composite events (HR 0.56; 95%-CI 0.33-0.97; P = .039). In tafamidis-treated patients, primary and secondary endpoints were associated with advanced NAC stage (P < .031; P < .009), age ≥80 years (P = .022; P = .004), and serum albumin ≤42.5 g/L (P = .015; P < .001), whereas NYHA class ≥III predicted only the composite endpoint (P = .059; P < .001).
conclusionsThis study provides long-term real-world outcome data for ATTR-CM patients treated with tafamidis based on physician clinical judgement. Adverse outcomes were strongly predicted by low serum albumin, advanced NAC stage, and older age, emphasizing the importance of early diagnosis and timely therapy of ATTR-CM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.